ISSN: 1859 - 2872
Recurrence-free survival and related factors after reoperation of radioactive iodine refractory differentiated thyroid cancer patients
Main Article Content
Keywords
Abstract
Objective: To assess recurrence-free survival and factors involved after surgery of radioactive iodine refractory differentiated thyroid cancer patients. Subject and method: We prospectively studied a cohort of 95 patients with radioactive iodine refractory differentiated thyroid cancer from December 2018 to November 2021 at 108 Military Central Hospital. Patients underwent recurrent resection entered the study. Recurrent tumor resection was considered the primary event, while the endpoint of the study was recurrence-free survival. Result: The median time follow up was 24 months. Twenty five patients had relapses. The mean recurrence-free survival was 37.06 months. According to the Kaplan-Meier tests, 1, 2, and 3-year recurrence-free survival were 94.4%, 80.6%, and 62.5%, respectively. In univariable and multivariable Cox proportional hazard analysis, factors such as tumor size and invaded recurrent tumor had an important association with recurrence-free years. Conclusion: Tumor size and invaded recurrent tumor are independent prognostic factors for recurrent-free survival in radioactive iodine refractory differentiated thyroid cancer.
Article Details
References
2. Lee HS, Roh JL, Gong G, Cho KJ et al (2015) Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent/persistent papillary thyroid carcinoma. World J Surg 39(8): 1943-1950.
3. Sun W, Di L, Chen L, Li D et al (2022) The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma. BMC Surg 22(1): 374.
4. Liu C, Chen T, Zeng W et al (2017) Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis. Sci Rep 7(1): 11412.
5. Kaliszewski K, Diakowska D, Nowak Ł et al (2020) The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice. BMC Cancer 20(1): 1166.
6. Saïe C, Wassermann J, Mathy E et al (2021) Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients. Eur J Endocrinol 184(5): 667-676.
7. Vianello F, Censi S, Watutantrige-Fernando S, et al (2021) The role of the size in thyroid cancer risk stratification. Sci Rep 11(1): 7303.
8. Randolph GW, Duh QY, Heller KS et al (2012) The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22(11): 1144-1152.
9. Xing M, Alzahrani AS, Carson KA et al (2015) Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33(1): 42-50.
10. Zhou TH, Lin B, Wu F et al (2021) Extranodal extension is an independent prognostic factor in papillary thyroid cancer: A propensity score matching analysis. Front Endocrinol (Lausanne) 12: 759049.
11. Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1): 1-133.
12. Xu S, Li Q, Wang Z, Huang H et al (2021) Evaluating the risk of re-recurrence in patients with persistent/recurrent thyroid carcinoma after initial reoperation. Surgery 169(4): 837-843.
Article Sidebar
